Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction
Authors:
- 18 June 2014
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 100 (1) , 38-50
Abstract
The past three decades have witnessed a great progress in the treatment of acute promyelocytic leukemia (APL). The current application of all-trans retinoic acid, arsenic trioxide (ATO), and anthracycline-based chemotherapies has been proved to be highly effective. Based on the risk factors of APL, optimization of the treatment emphasizes the role of ATO in induction, consolidation and maintenance therapy as a substitute to chemotherapy in low- and intermediate-risk patients, and in potential reduction of chemotherapy in high-risk group without impact on the outcome. However, early death and relapse remain obstacles to further improvement of the rates of remission and long-term survival, and the acute and chronic adverse effects of ATO should be considered for more appropriate management. Efforts should be made to more rationally obtain improved outcomes through the use of less toxic regimens.Keywords
This publication has 83 references indexed in Scilit:
- Impact of arsenic trioxide in the treatment of acute promyelocytic leukemiaLeukemia, 2011
- Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia RegistryLeukemia, 2011
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Blood, 2010
- Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxisHaematologica, 2009
- Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 2009
- Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicinBlood, 2008
- Chronic Arsenic Exposure and Cardiac Repolarization Abnormalities with QT Interval Prolongation in a Population-based StudyEnvironmental Health Perspectives, 2007
- Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapyPhilosophical Transactions of the Royal Society B: Biological Sciences, 2007
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Induced differentiation of a neuroblastomaDevelopmental Biology, 1971